
WE CLAIM:

1. A compound having the following formula IJ



IJ

a is a bond;

U^5 is C;

R^a, R^b are each independently H or halo or lower alkyl;

R^2 is

(i) an aryl optionally independently substituted with one or more lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy, or lower alkylamino, or

(ii) a heterocylo ring optionally independently substituted with one or more hydroxyl, BOC, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, oxo, lower alkoxy, or lower alkylamino;

R^{2a} and R^{2b} are independently selected at each occurrence from H or halo;

R^{10d} at each occurrence is independently –OMe, –OEt-OMe, -$OMeCF_3$, pyrazolylmethyl or isoxazolylmethyl;

wherein

n is 0;

n+ is 0, 1, 2 or 3;







q is 0;


or salts thereof

2. A compound of claim 1 wherein R^2 is phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,


pyridinyl, tetrahydropyridinyl, pyridinonyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, indolinonyl, isoidolinyl, isoindolinonyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzofuranyl, isobenzofuranyl, quinolinyl, isoquinolinyl, quinazolinyl, quinazolinonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, quinoxalinyl, tetrahydroquinoxalinyl, benzomorpholinyl, dihydrobenzodioxinyl, imidazopyridinyl, naphthyridinyl, benzotriazinyl, triazolopyridinyl, triazolopyrimidinyl, triazolopyridazinyl, imidazopyridinyl, imidazopyrimidinyl, imidazopyridazinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, cinnolinyl, thienopyrrolyl, tetrahydrothienopyrrolyl, dihydrothienopyrrolonyl, thienopyridinyl, thienopyrimidinyl, thienopyridazinyl, furopyridinyl, furopyrimidinyl, furopyrazidinyl, benzofuranyl, benzoimidazolyl, benzoisoxazolyl, benzothiazolyl, or benzoisothiazolyl any of which may be optionally independently substituted with one or more lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy, or lower alkylamino when R^2 is an aryl, or with one or more hydroxyl, BOC, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, oxo, lower alkoxy, or lower alkylamino when R^2 is a heterocyclo ring; or salts thereof.

3. A compound selected from:



,

,

,

,

,

,




,




,




,




,




,




,




,




,




,

















,



,



,


,

,

,

,

,

,

,

,

,

,

,

,

and

,

and salts thereof.

4. A pharmaceutical composition comprising a compound of claim 1 or salts thereof together with a pharmaceutically acceptable vehicle or carrier.


5. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for treating cancer in a subject.

6. The use of claim 5, wherein the medicament is to be used in combination with at least one compound selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and miscellaneous agents.


7. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for reducing tumor size in a subject.

8. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for reducing metastasis in a tumor in a subject.


9. A compound, or a pharmaceutically acceptable salt thereof according to claim 1, that is




10. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




11. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




12. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




13. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




14. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




15. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




16. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




17. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




18. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




19. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




20. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




21. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




22. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




23. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




24. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




25. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




26. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




27. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




28. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




29. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




30. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




31. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




32. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




33. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




34. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




35. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




36. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




37. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




38. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is



39. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is



40. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is



FUSED HETEROCYCLIC DERIVATIVES AND METHOD OF USE AS C-MET INHIBITORS

ABSTRACT

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

No suitable figure